Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
TOKYO, May 16, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered lenvatinib mesylate (product name: Lenvima, "lenvatinib", kinase inhibitor), eribulin mesylate (product name: Halaven, "eribulin", halichondrin class microtubule dynamics inhibitor), and MORAb-202 (antibody drug conjugate, ADC) will be given at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 31 to June 4, 2019.
The latest information on H3B-6527 (fibroblast growth factor receptor 4 inhibitor) and H3B-6545 (selective estrogen receptor covalent antagonist), which were discovered by Eisai's U.S. oncology precision medicine-focused research and development subsidiary H3 Biomedicine Inc., will also be highlighted in presentations at ASCO.
Major poster presentations at this year's meeting include highlights of the latest data from an ongoing Phase I clinical study investigating Eisai's first ADC MORAb-202 in patients with solid tumors in Japan. MORAb-202 is a novel ADC that combines Eisai's investigational anti-folate receptor (FRA) antibody farletuzumab with Eisai's in-house discovered anticancer agent eribulin as the payload.
Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.
About the Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Strategic Collaboration
In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co- commercialization of LENVIMA (lenvatinib). Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy KEYTRUDA (pembrolizumab).
In addition to ongoing clinical studies evaluating the LENVIMA and KEYTRUDA combination across several different tumor types, including renal cell carcinoma, the companies will jointly initiate new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program, which will evaluate the combination to support 11 potential indications in six types of cancer (endometrial cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, and urothelial cancer). The LEAP clinical program also includes a new basket trial targeting six additional cancer types (biliary tract cancer, breast cancer, colorectal cancer, gastric cancer, glioblastoma and ovarian cancer). The LENVIMA and KEYTRUDA combination is not approved in any cancer types today.
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit https://www.eisai.com
Public Relations Department
Eisai Co., Ltd.
Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.